What Marengo Therapeutics does

Marengo Therapeutics is a privately held, clinical-stage biotech founded in 2015 and headquartered in Cambridge, Massachusetts, that develops novel TCR-targeting antibodies to selectively modulate disease-specific T cell subsets for cancer and autoimmune indications. The company's scientific platform is built on three proprietary technology pillars — STAR (Bi-specific Selective Dual T Cell Agonists), TriSTAR (Tri-specific Precision T Cell Engagers), and MSTAR (Novel Precision T Cell Depleters) — each grounded in first-in-class antibody libraries that target germline-encoded Variable β (Vβ) chain variants of the T cell receptor, a mechanism distinct from checkpoint inhibitors and conventional bispecifics. The lead clinical asset, Invikafusp alfa (STAR0602), is a dual T cell agonist designed to selectively activate Vβ6/10 T cells, a subset highly prevalent in tumor-infiltrating lymphocytes; the candidate is being evaluated both as monotherapy and in combination with Gilead's TRODELVY across the STARt-001 and STARt-002 Phase 1/2 trials in PD-1-resistant solid tumors, with interim Phase 2 data showing 20% overall response rate and 80% disease control rate across seven tumor types and confirmed complete responses in metastatic breast cancer combinations.

Marengo operates pre-commercial, generating no product revenue, and distributes its investigational therapies exclusively through clinical trial enrollment at over 20 academic cancer centers across North America and Europe, including MD Anderson, Dana-Farber, Memorial Sloan Kettering, Gustave Roussy, and VHIO. The company's go-to-market economics are anchored on milestone-based strategic collaborations rather than direct commercialization: a 2024 partnership with Ipsen for co-development of STAR program assets is valued at up to $2.8 billion in upfront and milestone payments, and a 2024 collaboration with Gilead secures TRODELVY supply for the STARt-002 combination study. The company was incubated and is wholly backed by ATP (Apple Tree Partners), which provided the $80 million Series A in November 2021, and the FDA granted Fast Track designation to Invikafusp alfa in advanced colorectal cancer with TMB-H in January 2025. The company employs 11–50 people across research, clinical development, regulatory, and corporate functions, and markets itself primarily through scientific conferences (SITC, AACR, ESMO, SABCS) and peer-reviewed publications rather than traditional commercial channels.

Name

Marengo Therapeutics

Legal name

Marengo Therapeutics, Inc.

Website

https://marengotx.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Marengo Therapeutics is a clinical-stage biotech developing first-in-class TCR-targeting antibodies (STAR, TriSTAR, MSTAR platforms) that selectively modulate Vβ T cell subsets for cancer and autoimmune diseases, with lead asset Invikafusp alfa in Phase 2 trials across PD-1-resistant solid tumors.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industries

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• Cancer immunotherapy
• TCR-targeting antibodies
• Bispecific antibodies
• T cell agonists
• Oncology biologics

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Pipeline development and potential commercialization: As a clinical-stage biotech, Marengo is pre-revenue. The company is developing novel TCR-targeting antibody therapies for cancer treatment. Revenue potential exists through future product commercialization and strategic partnerships including co-development agreements and milestone payments.
2. Strategic partnerships and collaborations: Marengo has established strategic partnerships with Ipsen (valued at $2.8B) and Gilead Sciences for co-development of combination therapies. These partnerships generate upfront payments, milestone payments, and potential royalties on future sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Marengo Therapeutics is a clinical-stage biotech developing TCR-targeting antibody therapies through three proprietary platforms (STAR, TriSTAR, MSTAR) that selectively modulate disease-specific T cell subsets to combat cancer and autoimmune disease. The lead candidate, Invikafusp alfa (STAR0602), is in Phase 2 clinical trials for advanced solid tumors, including combination studies with TRODELVY for metastatic breast cancer. Multiple additional candidates (STAR0603, STAR0501, STAR0502, TriSTAR0701, TriSTAR0705, MSTAR0801) are advancing through preclinical and Phase 1 development, with select assets partnered with Ipsen.

Product overview

Marengo Therapeutics is a clinical-stage biotech company pioneering a novel approach to cancer immunotherapy through three proprietary technology platforms: STAR (Bispecific Selective Dual T Cell Agonists), TriSTAR (Tri-specific Precision T Cell Engagers), and MSTAR (Novel Precision T Cell Depleters). The lead product is invikafusp alfa (STAR0602), the first dual T cell agonist from the STAR platform that selectively activates Vβ6/10 T cells. The company is developing multiple candidates across these platforms including STAR0603, STAR0501 (partnered with Ipsen), STAR0502, TriSTAR0701 targeting Nectin-4, TriSTAR0705, and MSTAR0801 for autoimmune diseases. Invikafusp alfa is being studied as monotherapy and in combination with Gilead's TRODELVY in the STARt-002 trial for metastatic breast cancer.

Differentiator

Problem solved

Functional benefit

Brands

• STAR Platform: Bi-specific Selective Dual T Cell Agonists platform — first-in-class antibody library enabling selective modulation of Vβ TCR variants to activate specific T cell subsets for cancer treatment.
• TriSTAR Platform
• MSTAR Platform

Products and services

• Invikafusp alfa (STAR0602) First-in-class dual T cell agonist from the STAR platform that selectively activates Vβ6/10 T cells by combining non-clonal TCR activation with a T cell co-stimulatory signal in a single molecule. Being studied as monotherapy in STARt-001 across advanced solid tumors (including PD-1-resistant cancers and TMB-H colorectal cancer) and in combination with TRODELVY (sacituzumab govitecan) in the STARt-002 trial for metastatic breast cancer. FDA Fast Track designation granted in TMB-H colorectal cancer.
• STAR0603 Bispecific candidate from Marengo's precision T cell agonist STAR platform in development.
• STAR0501 STAR program candidate partnered with Ipsen under the $2.8B strategic partnership, advancing in Phase 1 clinical development.
• STAR0502 STAR program candidate partnered with Ipsen under the $2.8B strategic partnership.
• TriSTAR0701 (Nectin-4) Trispecific TriSTAR candidate targeting Nectin-4 for bladder and other solid tumor indications.
• TriSTAR0705 Trispecific TriSTAR candidate in development for oncology and autoimmune indications.
• MSTAR0801 MSTAR platform candidate using precision T cell depletion to address T cell-mediated autoimmune diseases.
• IPN60300 Antibody-drug conjugate (ADC) in Phase I/II trials, distinct from Marengo's core STAR platform programs.

Quantifiable outcome

• 20% overall response rate and 80% disease control rate in Phase 2 trial of Invikafusp alfa across seven major solid tumor types in PD-1-resistant cancers
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and major.

• IpsencoreStrategic or Co-development Partner · 1 January 2024Marengo established a strategic partnership with Ipsen valued at up to $2.8 billion for the co-development of STAR program assets including IPN01203/STAR0501. Ipsen is advancing the STAR0501 program in Phase 1, selected for presentation at AACR 2026's New Drugs on the Horizon session.
• Gilead SciencesmajorStrategic or Co-development Partner · 1 January 2024Collaboration with Gilead for supply of TRODELVY (sacituzumab govitecan) in the STARt-002 clinical trial investigating Invikafusp alfa in combination with TRODELVY for metastatic breast cancer. Marengo is the sponsor of the clinical study.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Werewolf Therapeutics: Werewolf Therapeutics develops tumor-activated immune modulators (PREDATOR platform) for cancer. Comparable to Marengo as a clinical-stage biotech developing novel immuno-oncology antibody-based therapeutics.
• Cullinan Oncology: Cullinan Oncology is a clinical-stage biotech developing diversified oncology therapeutics including T cell engagers and immune modulators. Comparable to Marengo as a clinical-stage oncology company with multiple programs and similar business model of licensing/partnering pipeline assets.
• Bolt Biotherapeutics: Bolt Biotherapeutics develops ISAC (Immune-Stimulating Antibody Conjugates) that combine tumor-targeting antibodies with immune stimulants. Comparable to Marengo as a clinical-stage cancer immunotherapy company developing next-generation antibody-based therapeutics.
• Compugen: Compugen is a clinical-stage biotech leveraging AI/computational biology to discover novel immune checkpoints and develop antibody-based cancer immunotherapies. Comparable to Marengo in its focus on T cell-based immuno-oncology approaches with antibody therapeutics, though Compugen's targets are computational predictions.

Direct peers

• Immunocore Holdings: Immunocore is a clinical-stage biotech developing TCR-based immunotherapies for cancer and infectious diseases, with FDA-approved tebentafusp. Most directly comparable to Marengo as both companies leverage TCR biology to redirect T cell responses against tumors, though Immunocore uses soluble TCRs while Marengo targets Vβ chain variants with antibodies.
• Adaptimmune Therapeutics: Adaptimmune develops engineered TCR-T cell therapies for solid tumors, including the FDA-approved Tecelra for synovial sarcoma. Highly comparable to Marengo given both companies leverage TCR biology to target cancer, though Adaptimmune's modality is cell therapy (TCR-T) versus Marengo's antibody-based approach.
• Harpoon Therapeutics: Harpoon Therapeutics developed T cell engagers (TriTACs and ProTriTACs) targeting solid tumors and was acquired by Merck. Directly comparable to Marengo's TriSTAR tri-specific T cell engager platform given both companies focus on engaging T cells to attack solid tumors with engineered antibody constructs.
• Janux Therapeutics: Janux Therapeutics develops T cell engagers (TRACTrs) for solid tumors using a tumor-activated masking technology. Directly comparable as a clinical-stage biotech focused on T cell engager therapeutics for cancer, with similar pipeline stage and target indications.
• Dragonfly Therapeutics: Dragonfly Therapeutics develops NK cell engagers and immune modulators using its TriNKET platform for oncology and autoimmune indications. Comparable to Marengo given its focus on engaging immune cells (NK cells via TriNKETs) for tumor killing, similar in approach to Marengo's T cell-focused platforms.

Broad incumbents

• Macrogenics: MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer, including bispecific DART molecules and antibody-drug conjugates. Comparable to Marengo as an established clinical-stage antibody therapeutics developer, with broader pipeline across multiple solid tumor types.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/marengotx
• LinkedInlinkedin.com/company/marengo-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marengo Therapeutics